[Evidence-based treatment of methotrexate-resistant rheumatoid arthritis. Cytokine antagonists].
Schnabel
A
A
Sana Rheumazentrum Baden-Württemberg, Klinik für Internistische Rheumatologie und Klinische Immunologie, Bad Wildbad. a.schnabel@sana-wildbad.de
Gross
W L
WL
D000911:Antibodies, Monoclonal / Q000494:pharmacology; D018501:Antirheumatic Agents / Q000008:administration & dosage / Q000494:pharmacology*; D001172:Arthritis, Rheumatoid / Q000188:drug therapy* / Q000378:metabolism; D016207:Cytokines / Q000037:antagonists & inhibitors*; D004334:Drug Administration Schedule; D004351:Drug Resistance; D000068800:Etanercept; D019317:Evidence-Based Medicine; D006801:Humans; D007074:Immunoglobulin G / Q000494:pharmacology; D000069285:Infliximab; D053590:Interleukin 1 Receptor Antagonist Protein; D007375:Interleukin-1 / Q000037:antagonists & inhibitors; D008727:Methotrexate / Q000494:pharmacology; D018124:Receptors, Tumor Necrosis Factor; D012795:Sialoglycoproteins / Q000494:pharmacology; D014409:Tumor Necrosis Factor-alpha / Q000037:antagonists & inhibitors
D000911:Antibodies, Monoclonal; D018501:Antirheumatic Agents; D016207:Cytokines; C507763:IL1RN protein, human; D007074:Immunoglobulin G; D053590:Interleukin 1 Receptor Antagonist Protein; D007375:Interleukin-1; D018124:Receptors, Tumor Necrosis Factor; D012795:Sialoglycoproteins; D014409:Tumor Necrosis Factor-alpha; D000069285:Infliximab; D000068800:Etanercept; D008727:Methotrexate